Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318584 · ClinicalTrials.gov registry record · Phase 2
Cefotetan Therapy for Escherichia Coli Infections
A Phase 2 study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT07318584 is a Phase 2 study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 84 participants.
The verdict
NCT07318584, a Phase 2 study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.
Interventions
- DRUG Cefotetan
- DRUG Carbapenems
- DRUG Beta Lactam Antibiotics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318584
The ClinicalTrials.gov registry entry for NCT07318584 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cefotetan is the first listed.
NCT07318584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07318584 about?
NCT07318584 is a clinical study titled "Cefotetan Therapy for Escherichia Coli Infections". This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum conce...
What is the current status of trial NCT07318584?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2026-03. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07318584?
The interventions under investigation include: Cefotetan (DRUG), Carbapenems (DRUG), Beta Lactam Antibiotics (DRUG).
Who is sponsoring clinical trial NCT07318584?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.